Identification of differentially expressed genes in responders and non-responders
tumor
TUMOR
To further assess the impact of the tumor immune microenvironment (TiME) on clinical response to sintilimab combined with GemCis, we performed extensive transcriptome analysis using NanoString nCounter assay in 28 of the 30 participants. The results of the transcriptome analysis on differential expression between responders and non-responders identified 24 significant genes (Fig. 